Literature DB >> 21796619

Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.

Annelies Fieuw1, Candy Kumps, Alexander Schramm, Filip Pattyn, Björn Menten, Francesca Antonacci, Peter Sudmant, Johannes H Schulte, N Van Roy, Sarah Vergult, Patrick G Buckley, A De Paepe, Rosa Noguera, Rogier Versteeg, Raymond Stallings, Angelika Eggert, Jo Vandesompele, Katleen De Preter, Frank Speleman.   

Abstract

Neuroblastoma is an aggressive embryonal tumor that accounts for ∼15% of childhood cancer deaths. Hitherto, despite the availability of comprehensive genomic data on DNA copy number changes in neuroblastoma, relatively little is known about the genes driving neuroblastoma tumorigenesis. In this study, high resolution array comparative genome hybridization (CGH) was performed on 188 primary neuroblastoma tumors and 33 neuroblastoma cell lines to search for previously undetected recurrent DNA copy number gains and losses. A new recurrent distal chromosome 1q deletion (del(1)(q42.2qter)) was detected in seven cases. Further analysis of available array CGH datasets revealed 13 additional similar distal 1q deletions. The majority of all detected 1q deletions was found in high risk 11q deleted tumors without MYCN amplification (Fisher exact test p = 5.61 × 10(-5) ). Using ultra-high resolution (∼115 bp resolution) custom arrays covering the breakpoints on 1q for 11 samples, clustering of nine breakpoints was observed within a 12.5-kb region, of which eight were found in a 7-kb copy number variable region, whereas the remaining two breakpoints were colocated 1.4-Mb proximal. The commonly deleted region contains one miRNA (hsa-mir-1537), four transcribed ultra conserved region elements (uc.43-uc.46) and 130 protein coding genes including at least two bona fide tumor suppressor genes, EGLN1 (or PHD2) and FH. This finding further contributes to the delineation of the genomic profile of aggressive neuroblastoma, offers perspectives for the identification of genes contributing to the disease phenotype and may be relevant in the light of assessment of response to new molecular treatments.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796619     DOI: 10.1002/ijc.26317

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

Review 2.  Effects of prenatal exposure to endocrine disruptors and toxic metals on the fetal epigenome.

Authors:  Paige A Bommarito; Elizabeth Martin; Rebecca C Fry
Journal:  Epigenomics       Date:  2017-02-17       Impact factor: 4.778

3.  Bioorthogonal oncometabolite ligation.

Authors:  Chloe A Briney; Susana Najera; Jordan L Meier
Journal:  Methods Enzymol       Date:  2019-03-14       Impact factor: 1.600

4.  Tolerance of DNA Replication Stress Is Promoted by Fumarate Through Modulation of Histone Demethylation and Enhancement of Replicative Intermediate Processing in Saccharomyces cerevisiae.

Authors:  Faeze Saatchi; Ann L Kirchmaier
Journal:  Genetics       Date:  2019-05-13       Impact factor: 4.562

Review 5.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

Review 6.  Fumarate hydratase in cancer: A multifaceted tumour suppressor.

Authors:  Christina Schmidt; Marco Sciacovelli; Christian Frezza
Journal:  Semin Cell Dev Biol       Date:  2019-05-22       Impact factor: 7.727

7.  Photoinducible Oncometabolite Detection.

Authors:  Rhushikesh A Kulkarni; Chloe A Briney; Daniel R Crooks; Sarah E Bergholtz; Chandrasekhar Mushti; Stephen J Lockett; Andrew N Lane; Teresa W-M Fan; Rolf E Swenson; W Marston Linehan; Jordan L Meier
Journal:  Chembiochem       Date:  2018-12-13       Impact factor: 3.164

8.  Exploring the associations between microRNA expression profiles and environmental pollutants in human placenta from the National Children's Study (NCS).

Authors:  Qian Li; Maya A Kappil; An Li; Priyanthi S Dassanayake; Thomas H Darrah; Alan E Friedman; Michelle Friedman; Luca Lambertini; Philip Landrigan; Christopher J Stodgell; Yulin Xia; Jessica A Nanes; Kjersti M Aagaard; Eric E Schadt; Jeff C Murray; Edward B Clark; Nancy Dole; Jennifer Culhane; James Swanson; Michael Varner; Jack Moye; Carol Kasten; Richard K Miller; Jia Chen
Journal:  Epigenetics       Date:  2015-08-07       Impact factor: 4.528

9.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

Review 10.  Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy.

Authors:  Yueming Zhu; Angela Elizabeth Dean; Nobuo Horikoshi; Collin Heer; Douglas R Spitz; David Gius
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.